Latest Breaking News On - Ramy mahmoud - Page 5 : comparemela.com

The breath-powered device delivers a standard drug deep into the nasal cavity for a clinically different product. About 30 million Americans suffer from chronic rhinosinusitis, Ramy Mahmoud, M.D., tells MD+DI, and the condition “causes a lot of distress and impairment,” he says. About 10 million of these patients have nasal polyps and use nasal corticosteroid sprays for relief. Many patients remain symptomatic, however, and they often turn to injections or even surgery, explains Mahmoud, who serves as president of Optinose.   A system from Optinose for delivering those corticosteroids deep in the nasal cavity may enable an effective next-step treatment option before injections or surgery, according to a recent study. The system is US FDA approved for the treatment of nasal polyps in patients 18 years of age or older and is marketed with fluticasone in the new delivery system under the trade name XHANCE. Published in the 

United statesRamy mahmoudInternational forum of allergy rhinologyAmerican rhinologic societyInternational forumPackaging digestஒன்றுபட்டது மாநிலங்களில்ராமி மஹ்மூத்சர்வதேச மன்றம்ப்யாகேஜிஂக் ஜீரணிக்கவும்